<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620318</url>
  </required_header>
  <id_info>
    <org_study_id>ARO-EAP</org_study_id>
    <nct_id>NCT03620318</nct_id>
  </id_info>
  <brief_title>Individual Patient Compassionate Use of Crenolanib</brief_title>
  <official_title>Compassionate Use of Crenolanib for Cancers With Platelet Derived Growth Factor Receptor Alpha (PDGFRa) Mutations, PDGFRa Amplifications or Fms-like Tyrosine Kinase 3 (FLT3) Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arog Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arog Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      Compassionate use of crenolanib for patients with serious life-threatening illness that have&#xD;
      exhausted all available therapies used to treat the disease, with no other viable therapy&#xD;
      options, who is not eligible for clinical trials. This program is designed to evaluate the&#xD;
      requests on a patient by patient basis.&#xD;
&#xD;
      Patients must have documented evidence of a point mutation in position 842 in platelet&#xD;
      derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal&#xD;
      tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within&#xD;
      the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This program is being offered on a patient by patient basis while phase 3 studies with&#xD;
      crenolanib are ongoing.&#xD;
&#xD;
      Institutional Review Board-/Independent Ethics Committee approval must be granted before, The&#xD;
      experimental intervention will be administered over 28-day cycles. Compassionate use of&#xD;
      crenolanib will be limited such that it does not interfere with the supply need for phase 3&#xD;
      studies.&#xD;
&#xD;
      There must be adequate understanding of the indication for the requested use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>FLT3-ITD Mutation</condition>
  <condition>FLT3/TKD Mutation</condition>
  <condition>PDGFR-Alpha D842V</condition>
  <condition>PDGFRA Gene Amplification</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenolanib besylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must have a serious life threatening cancer with FLT3/PDGFRa mutation or&#xD;
             PDGFRa amplification who has exhausted all other treatment options&#xD;
&#xD;
          -  Subject and their partner (if adults) must use 2 forms of contraception during study&#xD;
             and for 3 months following last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is eligible for enrollment in an ongoing clinical trial&#xD;
&#xD;
          -  Subject has any condition which, in the investigator's opinion makes the subject&#xD;
             unsuitable for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Vinay Jain, MD</last_name>
    <phone>214-593-0500</phone>
    <email>info@arogpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Emanuele Angelucci, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Compassionate use</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crenolanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

